KBLM News and Press, KBL Merger IV From 10/16/20

FY2020 till date has seen 127 SPAC IPOs, which collectively raised over $48.5B in proceeds, much more than the past ten years combined.Going public via a SPACs is a cost-effective way of doing an M&A deal in weeks instead of months, and its proving to be an especially attractive vehi...

NEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- 180 Life Sciences Corp. today announces its placement in an editorial published by Network NewsWire ("NNW"), one of 50+ brands in the InvestorBrandNetwork (“IBN”), a multifaceted financial news and ...

180 Life Sciences is a clinical-stage biotechnology company that is developing therapies to combat inflammation in patients with chronic inflammation-related illnesses The company is being acquired by special purpose acquisition corporation KBL Merger Corp. IV (NASDAQ: KBLM) and will be l...

180 Life Sciences , a clinical-stage biotechnology company, is focused on the development of novel drugs that fulfill unmet needs for a variety of conditions including fibrosis, pain and inflammatory diseases. 180 Life Sciences will soon form a combined company with KBL Merger Corp. IV (NASDA...

180 Life Sciences boasts a world-class team responsible for developing new classes of drugs targeting multiple disease states while creating significant shareholder value The company has a large and expanding patent portfolio The risks associated with the company’s drug developme...

IPOs are the past The casting couch... Outer borough pit traders with a feeling about how to price some options... A baseball player’s rugged jawline: Every industry had their pre- Moneyball ways of making choices based on favors, hunches, and biases. People did things that w...

KBL Merger Corp. (NASDAQ: KBLM), a special purpose acquisition corporation (“SPAC”) that previously announced the signing of a definitive agreement to acquire CannBioRx Life Sciences Corp. (now to be referred to as "180 Life Sciences"), on Monday announced successful closing of a...

NEW YORK , June 29, 2020 /PRNewswire/ -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition corporation (SPAC) that previously announced the signing of a definitive agreement to acquire CannBioRx Life Sciences Corp. (now to be referred to as "180 Lif...

NEW YORK , July 26, 2019 /PRNewswire/ -- KBL Merger Corp. IV (NASDAQ: KBLM) ("KBLM"), a Special Purpose Acquisition Company (SPAC), announced today that it has executed a definitive business combination agreement for the merger of a wholly owned subsidiary of KBLM with CannBioRx Life Scie...

NEW YORK , May 14, 2019 /PRNewswire/ -- KBL Merger Corp. IV ("KBL" or "the Company") (NASDAQ: KBLM), a special purpose acquisition corporation, or SPAC, that completed its IPO in June 2017 , announced today that it has entered into a non-binding term sheet to acquire CannBioRx Life ...